DocGo’s Guidance Reset Narrows EBITDA Loss Outlook, Sparks “Buy the Rumor” Trade

The market's reaction to DocGo's fourth-quarter report was a classic case of expectations being reset. While the headline numbers showed a clear beat and a miss, the stock's strong rally tells the real story: investors were looking past the quarterly print and focusing on the forward view.

The numbers themselves present a mixed picture. Revenue came in at $74.9 million, beating the consensus estimate of $71.8 million. That's a solid beat. But the earnings per share figure was a significant miss, with the company reporting a GAAP loss of $0.53 per share against a consensus expectation for a loss of just $0.13. On the surface, this looks like a negative surprise.

Yet the stock jumped 8.42% after the close. This "sell the news" dynamic is common when the market had already priced in a worse outcome. The key context is the massive year-over-year decline in total revenue, which fell from $120.8 million last year. That drop was entirely due to the planned wind-down of migrant-related programs that were a major revenue driver in 2024. The market had likely braced for a steep drop, so the actual beat on top-line revenue-especially when excluding those one-time programs-was a relief.

The real expectation gap, however, opened up with the guidance. The company raised its 2026 revenue and adjusted EBITDA outlook, citing customer expansions and efficiency gains. This forward-looking optimism was the catalyst for the stock's pop. In other words, the market looked past the quarterly miss and bought the rumor of a better path ahead.

The Guidance Reset: Narrowing the Losses, Not the Horizon

The real expectation gap opened with the guidance. While the quarterly beat provided a relief rally, it was the forward view that shifted the market's calculus. Management raised its 2026 outlook, signaling a belief that cost initiatives and new customer expansions are starting to drive tangible margin improvement.

The revised numbers are telling. The company lifted its full-year revenue guidance to a range of $290 million–$310 million, up from the prior $280 million–$300 million. More importantly, the adjusted EBITDA loss guidance was sharply tightened. The new range of $5 million–$10 million represents a massive improvement from the previous $15 million–$25 million loss forecast. This is a clear narrowing of the financial horizon.

This guidance reset is the market's new focus. It signals management's confidence that the efficiency programs and new business growth are gaining traction. The company highlighted a portfolio of initiatives projected to deliver $5 million–$6 million in 2026 savings, with annualized benefits of $20 million–$24 million by 2027. The improved gross margin at SteadyMD and the strong growth in non-migrant mobile health segments provide the operational proof points for this optimism.

For investors, the guidance shift means the market's focus is now on execution against these tighter targets. The raised revenue range sets a higher bar, while the narrowed EBITDA loss guidance demands that cost savings materialize. The stock's post-earnings pop suggests the market is buying the rumor of a better path ahead, but the reality check will come in the quarters to follow.

The SteadyMD Engine and the Care Gap Play

The strategic pivot to care gap closure is now the core of DocGo's growth thesis, and the numbers show it's gaining traction. The key engine is SteadyMD, the post-acquisition unit that contributed $6.1 million in Q4 revenue. More importantly, its gross margin improved to 37% for the year, up from approximately 30% the prior year. This margin expansion is critical-it demonstrates that the technology platform is not just adding revenue but doing so profitably, which directly supports the company's narrowed EBITDA loss guidance.

The expansion of care gap services is the operational fuel for this engine. The company reported a 12% sequential increase in assigned lives, pushing the total to over 1.45 million. This growth is being driven by new customer expansions, including a major national insurance payer in Kentucky. This isn't just incremental; it's a scalable model where DocGo uses its mobile health network to proactively identify and close gaps in patient care, turning a cost center into a revenue-generating service line.

This pivot is the direct link to the 2026 growth thesis. The 47% year-over-year increase in non-migrant mobile health revenue was powered by this exact strategy. It shows the market is moving past the one-time wind-down of migrant programs and betting on the recurring, higher-margin business of care gap closure. The SteadyMD acquisition and its margin improvement provide the technological and operational proof point for that bet. For the stock to sustain its rally, execution on this play-adding more assigned lives and converting them to revenue-will need to meet the raised 2026 targets.

Catalysts and Risks: The Path to a "Buy the Rumor" Turn

The stock's post-earnings pop was a classic "sell the news" reaction to a quarter that had already been discounted. Now, the market is poised to move from that relief rally to a "buy the rumor" phase, betting that the raised 2026 guidance is credible. The path forward hinges on a few near-term catalysts and a clear-eyed view of the risks.

The primary catalyst is execution. Management highlighted new customer expansions as a key driver for the guidance raise. The first major test is the rollout of care gap closure services with a major national insurance payer in Kentucky. Success here would validate the scalability of the new business model and provide a tangible proof point for the 47% year-over-year growth in non-migrant mobile health revenue. Another near-term event is the formal process to explore strategic alternatives, which could act as a catalyst if it leads to a potential sale or partnership that unlocks value faster than organic growth.

Yet the major risk is a potential for further operating losses in the first half of 2026. The company's adjusted EBITDA loss came in slightly worse than anticipated last quarter due to wind-down costs, and the new guidance still expects a loss. This means the company must generate significant cash flow from operations to cover its losses and fund growth, especially as it ramps up new customer programs. The decline in cash and cash equivalents to $68.3 million at year-end, partly due to delayed collections, underscores the pressure on working capital. Any delay in revenue recognition or higher-than-expected burn could quickly erode the cash buffer and force a reassessment of the timeline for profitability.

The bottom line is that the current optimism is a bet on execution. The stock's move from "sell the news" to "buy the rumor" depends on the company hitting its tightened 2026 targets. The catalysts-new customer wins and strategic alternatives-are positive, but they must overcome the near-term risk of continued losses and cash pressure. Investors are now looking past the quarterly print and focusing on the 2026 path, where the expectation gap will be closed only by delivering on the raised guidance.